Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 95.50
Bid: 95.00
Ask: 96.00
Change: 0.50 (0.53%)
Spread: 1.00 (1.053%)
Open: 95.00
High: 95.50
Low: 95.20
Prev. Close: 95.00
CNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

26 Sep 2022 07:00

RNS Number : 5353A
Concurrent Technologies PLC
26 September 2022
 

This announcement contains inside information

Concurrent Technologies PLC

(the "Company")

Interim Results for the six months ended 30 June 2022

 

Concurrent Technologies PLC (AIM: CNC), a world leading specialist in high-end embedded computer products for critical applications, announces its interim results for the six months to 30 June 2022 ("H1 2022").

 

Financial Performance

Component supply issues have delayed shipping of some of the Company's products, such that a proportion of expected H1 2022 revenues will be recognised in a later period. However, this is a short-term issue and in no way relates to the quality of the underlying business. Demand for the Company's products is higher than ever with a strong H1 order book (£14.2M) and record backlog (£20.3M).

· Revenue of £7.4M (H1 2021: £9.3M) - reduced solely as a result of components supply issues

· Gross profit of £3.7M (H1 2021: £5.1M)

· Gross margin of 50.4% (H1 2021: 54.3%) - reduced as the result of price increases of some components due to high demand and limited supply (-£0.3M against H1 revenue)

· Operating profit of £0.1M (H1 2021: £1.6M) - predominantly driven by revenue/gross margin variance of -£1.4M; net costs increased by c£0.2M, in line with investment strategy

· Profit before tax of £0.0M (H1 2021: £1.6M)

· EPS of 0.75 pence (H1 2021: 2.09 pence)

· Interim dividend suspended for H1 2022 (H1 2021: 1.15 pence per share)

· Cash Balance (including cash deposits) as at 30 June 2022 of £9.3M (31st Dec 2021: £11.8M)

reduced due to lower cashflow from operations of £0.6M, and continued investment of £3M, in line with our strategy

R&D investment will continue into H2 2022 at a similar level as H1 2022

 

Operational Summary

· Strong order intake of £14.2M as at 30 June 2022, with significant backlog of £20.3M compared to £15.6M backlog as at 30 June 2021, up 30%

· Defence is largest market sector at 76% revenue

· Global customer base is solid with exports generating 90% of revenue

· R&D costs (talent, improved process & analysis, materials) have increased by 50% to £2.4M (H1 2021 £1.6M), in line with stated strategy to enhance the number of product releases per annum and reflect the more complex nature of our offerings

· Three new products launched in H1 2022 and on track to launch eight new products during FY2022 (approx. double previous cadence)

· Component shortages have been exceptionally challenging, causing a significant limitation to our ability to ship product

· Major new order with a Fortune 500 medical company with a $2.3M purchase order in 2022 and similar sized orders anticipated for several years to come

· Experienced leadership team fully in place

· New office opened in Theale to attract and retain talent

· 20% increase in headcount, in line with strategy, to enhance new product delivery and support our path to growth

Miles Adcock, CEO of Concurrent Technologies, commented: "Short term component availability is resulting in constrained performance in FY2022, with limited visibility of exactly when it will ease. However, order intake is strong, and would otherwise reflect in a solid improvement in revenues. Order intake should strengthen further as strategic initiatives take effect in FY2023 and beyond. Post period end, total order intake has further strengthened to £20.8M, producing a current backlog of £24.2M as at 12 September 2022. After more than a full year now leading this business, I am even more confident in our ability to grow and develop a successful global enterprise." 

 

 

CHAIRMAN'S STATEMENT

Whilst it is clearly disappointing the component supply issue has impacted on our revenues and profitability in the first half of 2022, which will continue in the second half of the year, it is important not to lose sight of the improving underlying fundamentals of the business, demonstrated in our product development, new customers, order intake, backlog and management strength. The component supply issues will ease and, although we can't be sure exactly when, when they do we are well positioned to benefit from all the underlying fundamentals highlighted, which will drive long term growth.

The cash position of the Company remains strong, which has allowed us to continue to invest in engineering and product development. The long term success of any technology company is bringing innovative new products to market first and that is, and will remain, our focus.

Given the strong balance sheet, paying an interim dividend out of historical retained earnings was considered.  However, paying dividends from current year earnings is an important discipline we wish to maintain. We are committed to paying a dividend and our shareholders will see the benefit of this as we drive growth in the coming years.

 

CHIEF EXECUTIVE'S REVIEW

Financial Summary

The Company has continued to operate in a very challenging environment in H1 2022. The global component shortage impacts the entire electronics sector and has had a significant impact on short term performance. The delay in completing the full manufacture of certain products, and a consequent delay in their shipping, has resulted in deferred invoicing and a corresponding reduction in revenue in the period against the prior year by 20% to £7.4M (H1 2021: £9.3M).

It is important to note that the impacted revenue is delayed and not lost, and we continue to recognise an exceptional backlog. We have strong relationships with our customers and are driving the pace for delivery. It is recognised by the customer base that the issues are driven by external factors (which all our competitors are also facing).

Demand driven increase in the costs of some components has also resulted in a reduction in gross margin of c.7% from 54.3% to 50.4%. Both revenue and gross margin impacts are solely driven by component shortages and are not a reflection of the quality of our underlying business. We have delivered an unaudited profit before tax (PBT) of £0.0M (H1 2021: £1.6M), a net variance of -£1.6M, primarily caused by the reduction in revenue volume and gross margin, with underlying net costs having increased by £0.2M (as per strategy, this is predominantly driven by investment in talent).

The balance sheet remains strong with no debt and £9.3M of cash balances (including cash deposits) as at 30 June 2022 (31 December 2021: £11.8M). In response to the components shortage, there has been a substantial and carefully managed investment in additional inventory, with an increase of £2.8M, to £9.4M (H1 2021: £6.6M). As the global supply chain recovers, and components become available, revenue generation will accelerate as the business not only delivers normal run rate outputs, but also increases capacity to enable the processing of the now record backlog (£20.3M at 30th June 2022 compared to £15.6M at 30 June 2021). Whilst the backlog is to some degree inflated due to the challenges of supply, it is important to note that FY2021 order intake was at a record level (£25.2M), and an order intake of £14.2M in H1 2022 puts the business on track to secure another very strong year of customer commitment.

 

Review of Operations

Despite the headwind generated by short term components shortages, the business is making good progress with operational improvement and implementation of the strategy.

A refreshed leadership team is now complete, with the new CFO Kim Garrod, being the most recent joiner in May 2022. We have also recruited additional talent across the organisation in engineering and sales, as well as fully implementing new functions such as HR and Legal/Commercial, growing our headcount from 99 to 118 in the last 12 months.

We have previously stated that it is imperative that we deliver more products to market in a timelier fashion. Having set the challenge of broadly doubling our cadence of new product releases to eight this year, we have indeed released three new products in the first half of 2022 and remain on track to achieve the objective of eight for the full year. This is reflected in a 100% increase in the cost of capitalised R&D compared to H1 2021.

We said we would develop a Build to Print partner in the USA to better access that domestic market. We have now qualified Nextek, based in Madison, Alabama. The intent is to be able to offer to the market genuinely 'Assembled in the USA' products by the end of 2022.

In addition to designing and manufacturing single board computers, we committed to invest in developing a systems business. Having recruited specialist experts during H1, and engaging in business development dialogue with potential partners and customers, we will secure initial contracts with new customers in H2 2022. An example of another new customer relationship that we have developed is the $2.3M purchase order from a Fortune 500 medical sector business, with the opportunity for similar size purchase orders from the same customer for several years to come.

 

Current Trading & Outlook

With a record H1 backlog of £20.3M, and a record YTD Order In-take of £20.8M (as at 12 September 2022), the business is starting to benefit from the refreshed approach to operations and strategy. We have transformed from primarily relying on end of life products in recent years, to four fifths of our orders this year being for our current and new products, which are exciting existing and new customers. In addition to increased demand from the market, we have built increased capacity to deliver through additional shifts and a qualified build to print partner in the United States. Whilst the challenge of securing semiconductor components is frustratingly constraining everyone's ability to ship completed product, we are well positioned for material growth as the situation resolves.

 

 

 

 

 

Condensed Consolidated Statement of Comprehensive Income

Unaudited interim results to 30th June 2022

Six months

 

Six months

 

Year

 

ended

 

ended

 

ended

 

Note

30/06/22

 

30/06/21

 

31/12/21

 

CONTINUING OPERATIONS

 

£

 

£

 

£

 

Revenue

 

7,421,285

9,315,839

20,450,453

Cost of sales

3,680,258

4,255,669

9,016,878

Gross profit

 

3,741,027

5,060,170

11,433,575

Net operating expenses

3,688,676

3,439,699

7,889,921

Group operating profit

 

52,351

1,620,471

3,543,654

Interest Costs

(26,930)

(32,233)

(61,679)

Finance income

6,992

3,696

1,880

Other Income

-

-

-

Profit before tax

 

32,413

1,591,934

3,483,855

Tax

(518,890)

56,559

638,412

Profit for the period

 

551,303

1,535,375

2,845,443

Other Comprehensive Income

 

Exchange differences on translating foreign operations

100,789

(19,626)

23,894

Tax relating to components of other comprehensive income

-

-

-

Other Comprehensive Income for the period, net of tax

100,789

(19,626)

23,894

Total Comprehensive Income for the period

 

652,092

1,515,749

2,869,337

Profit for the period attributable to:

 

Equity holders of the parent

551,303

1,535,375

2,845,443

Total Comprehensive Income attributable to:

 

Equity holders of the parent

652,092

1,515,749

2,869,337

Earnings per share

 

Basic earnings per share

4

0.75p

2.09p

 3.88p

Diluted earnings per share

4

0.75p

2.09p

 3.88p

Adjusted earnings per share

0.75p

2.09p

 3.72p

 

 

 

CONDENSED CONSOLIDATED BALANCE SHEET

Unaudited interim results to 30th June 2022

As at

 

As at

 

As at

 

30/06/22

 

30/06/21

 

31/12/21

ASSETS

 

£

 

£

 

£

Non-current assets

 

Property, plant and equipment

2,445,996

1,735,125

1,436,009

Intangible assets

9,058,713

7,333,105

7,692,528

Deferred tax assets

7,243

88,455

31,042

Other Financial Assets

-

-

-

11,511,952

9,156,685

9,159,579

Current assets

 

Inventories

9,460,432

6,619,081

6,425,436

Trade and other receivables

3,460,344

2,614,711

2,988,633

Current tax assets

597,086

351,104

330,748

Other Financial Assets

-

-

-

Cash and cash equivalents

9,265,663

12,386,445

11,839,758

22,783,525

21,971,341

21,584,575

Total assets

 

34,295,476

31,128,026

30,744,154

LIABILITIES

 

Non-current liabilities

 

Deferred tax liabilities

2,176,884

1,638,947

2,193,418

Trade and other payables (LT Lease)

505,767

518,919

570,576

Long term provisions

18,256

18,256

19,172

2,700,907

2,176,122

2,783,166

Current liabilities

 

Trade and other payables

7,119,058

5,625,215

4,196,272

Short term provisions

18,256

18,256

19,300

Current tax liabilities

15,779

33,190

4,817

7,153,093

5,676,661

4,220,389

Total liabilities

 

9,854,000

7,852,783

7,003,555

Net assets

 

24,441,476

23,275,243

23,740,599

EQUITY

 

Capital and reserves

 

Share capital

739,000

739,000

739,000

Share premium account

3,699,105

3,699,105

3,699,105

Capital redemption reserve

256,976

256,976

256,976

Cumulative translation reserve

3,390

(140,919)

(97,399)

Profit and loss account

19,743,006

18,721,081

19,142,917

Equity attributable to equity holders of the parent

24,441,477

23,275,243

23,740,599

Total equity

 

24,441,477

23,275,243

23,740,599

 

 

Condensed Consolidated Cash Flow Statement

 

Unaudited interim results to 30th June 2022

 

 

Six months

 

Six months

 

Year

 

ended

 

ended

 

ended

 

30/06/2022

 

30/06/2021

 

31/12/2021

 

£

 

£

 

£

Cash flows from operating activities

 

Profit before tax for the period

32,413

1,591,934

3,483,855

Adjustments for:

Finance income

(6,992)

(3,696)

(1,880)

Finance costs

26,930

32,233

61,679

Depreciation

121,589

84,757

288,560

Amortisation

627,395

606,453

1,234,655

Impairment loss

-

150,000

570,812

Loss on disposal of property, plant and equipment (PPE)

-

28,778

27,401

Share-based payment

48,785

16,339

12,963

Exchange differences

111,153

(16,762)

46,623

(Increase)/decrease in inventories

(3,034,996)

(1,085,507)

(891,862)

(Increase)/decrease in trade and other receivables

(471,711)

(258,554)

(632,476)

Increase/(decrease) in trade and other payables

2,920,826

1,645,319

330,735

Cash generated from operations

375,392

2,791,294

4,531,065

Tax (paid)/received

270,780

(21,110)

(40,274)

Net cash generated from operating activities

646,172

2,770,184

4,490,791

Cash flows from investing activities

 

Interest received

6,992

3,696

1,880

Cash placed on deposit

-

-

-

Purchases of property, plant and equipment (PPE)

(1,124,354)

(115,045)

(185,879)

Proceeds from sale of PPE

-

-

1,500

Purchases of intangible assets

(1,993,577)

(883,983)

(2,124,529)

Net cash used in investing activities

(3,110,939)

(995,332)

(2,307,028)

Cash flows from financing activities

 

Equity dividends paid

-

(1,063,769)

(1,907,447)

Repayment of leasing liabilities

(64,809)

(56,871)

(117,613)

Interest paid

(26,930)

(32,233)

(61,679)

Cash received from share issue

-

-

-

Purchase of treasury shares

-

-

-

Net cash used in financing activities

(91,739)

(1,152,873)

(2,086,739)

Effects of exchange rate changes on cash and cash equivalents

(17,589)

(1,508)

(23,240)

Net increase/(decrease) in cash

 

(2,574,095)

620,471

73,784

Cash at beginning of period

11,839,758

11,765,974

11,765,974

Cash at the end of the period

9,265,663

12,386,445

11,839,758

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Unaudited interim results to 30th June 2022

Capital

 

Cumulative

 

Profit

 

Share

 

Share

 

redemption

 

translation

 

and loss

 

Total

 

capital

 

premium

 

reserve

 

reserve

 

account

 

Equity

 

£

 

£

 

£

 

£

 

£

 

£

Balance at 1 January 2021

739,000

3,699,105

256,976

(121,293)

18,271,819

22,845,607

Profit for the period

-

-

-

-

1,535,375

1,535,375

Exchange differences on translating foreign operations

-

-

-

(19,626)

-

(19,626)

Total recognised comprehensive income for the period

-

-

-

(19,626)

1,535,375

1,515,749

Share-based payment

-

-

-

-

16,339

16,339

Deferred tax on share based payment

-

-

-

-

(38,683)

(38,683)

Dividends paid

-

-

-

-

(1,063,769)

(1,063,769)

Sale of treasury shares

-

-

-

-

-

-

Issue of Ordinary shares

-

-

-

-

-

-

Balance at 30 June 2021

739,000

3,699,105

256,976

(140,919)

18,721,081

23,275,243

Total recognised comprehensive income for the period

-

-

-

-

1,310,059

1,310,059

Exchange differences on translating foreign operations

-

-

-

43,520

-

43,520

Total recognised comprehensive income for the period

-

-

-

43,520

1,310,059

1,353,579

Share-based payment

-

-

-

-

(3,376)

(3,376)

Deferred tax on share based payment

-

-

-

-

(41,169)

(41,169)

Dividends paid

-

-

-

-

(843,678)

(843,678)

Sale of treasury shares

-

-

-

-

-

-

Balance at 31 December 2021

739,000

3,699,105

256,976

(97,399)

19,142,917

23,740,599

Total recognised comprehensive income for the period

-

-

-

-

551,303

551,303

Exchange differences on translating foreign operations

-

-

-

100,789

-

100,789

Total recognised comprehensive income for the period

-

-

-

100,789

551,303

652,092

Share-based payment

-

-

-

-

48,785

48,785

Deferred tax on share based payment

-

-

-

-

1

1

Dividends paid

-

-

-

-

-

-

Issue of ordinary shares

-

-

-

-

-

-

Sale of treasury shares

-

-

-

-

-

-

Balance at 30 June 2022

739,000

3,699,105

256,976

3,390

19,743,006

24,441,477

 

NOTES TO THE INTERIM REPORT

1. General information

The principal activity of the Group is design, manufacture and supply of innovative high-end embedded single board computers and complementary accessories aimed at a wide base of customers within the defence & aerospace, telecommunications, medical and other markets.

Concurrent Technologies PLC ("the Company") is the Group's ultimate parent company. It is incorporated and domiciled in Great Britain. Concurrent Technologioes PLC shares are listed on the Alternative Investment Market of the London Stock Exchange.

The Group's condensed consolidated interim financial statements are presented in pounds sterling (£), which is also the functional currency of the parent company.

These condensed consolidated interim financial statements, which are unaudited, have been approved for issue by the Board of Directors on 23rd September 2022.

The information relating to the six months ended 30th June 2022 is unaudited and does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The statutory accounts for the year ended 31st December 2021, prepared in accordance with IFRSs (International Financial Reporting Standards) as adopted by the European Union, have been reported on by the Group's auditors and delivered to the Registrar of Companies. The auditor's report was qualified, and this qualification will be addressed in the statutory accounts for 31st December 2022.

2. Summary of significant accounting policies

 

2.1 Basis of preparation

 

These condensed consolidated interim financial statements are for the six months period ended 30th June 2022. They have been prepared in accordance with IAS 34 "Interim Financial Reporting". They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31st December 2021, which have been been prepared in accordance with adopted IFRSs.

The accounting policies applied and methods of computation are consistent with those of the annual financial statements for the year end 31st December 2021, as described in those financial statements. The accounting policies have been consistently applied to all the periods presented.

There are no new IFRSs or IFRIC interpretations that are effective for the first time for the financial period beginning on or after 1st January 2022 that would be expected to have a material impact on the results or financial position of the Group.

2.2 Going Concern

The Directors are satisfied that the Group has sufficient resources to continue in operation for the foreseeable future, a period of not less than 12 months from the date of this report. Accordingly the continue to adopt the going concern basis in preparing these condensed financial statements.

2.3 Taxation

Current tax expense is recognised in these condensed consolidated interim financial statements based on the estimated effective tax rates for the full year.

 

3. Segmental reporting

The Directors consider that the Group is engaged in a single segment of business, being design, manufacture of high-end embedded computer products and that therefore, the Company has only a single operating segment. The key measure of performance used by the Board to assess the Group's performance is the Group's profit before tax, as calculated under IFRS, and therefore no reconciliation is required between the measure of profit or loss used by the Board and that contained in the condensed consolidated interim financial statements.

4. Earnings per share

Basic earnings per share is calculated by dividing the profit attributable to ordinary equity holders for the period by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share is calculated adjusting the weightesd average number of ordinary shares outstanding to assume conversion of all contracted dilutive potential ordinary shares. The Company only has one category of dilutive potential ordinary shares, namely share options.

The inputs to earnings per share calculation are shown below:

 

Six months

 

Six months

 

Year

 

ended

 

ended

 

ended

 

30/06/22

 

30/06/21

 

31/12/21

 

£

 

£

 

£

Profit attributable to ordinary equity holders

551,303

1,535,375

2,845,443

Six months

 

Six months

 

Year

 

ended

 

ended

 

ended

 

30/06/22

 

30/06/21

 

31/12/21

 

 

 

 

Weighted average number of ordinary shares for basic earnings per share

73,363,490

73,673,490

73,363,490

Adjustment for share options

-

Weighted average number of ordinary shares for diluted earnings per share

73,363,490

73,673,490

73,363,490

 

 

 

 

 

5. Shareholder Communication

A copy of these condensed interim financial statements is available from the Company's Registered office at:

4 Gilberd Court,

Newcomen Way,

Colchester,

Essex, UK

CO4 9WN

They are also available from the Company's website at www.gocct.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR UVSORUUUKUAR
Date   Source Headline
24th Apr 20247:00 amRNSUS Contract Win and Notice of Results
9th Apr 20247:00 amRNSNew Product Announcement
5th Feb 20247:00 amRNSBoard Appointment
17th Jan 20247:00 amRNSTrading update
21st Dec 20237:00 amRNSKey VME Contract Win
19th Dec 20231:07 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSTrading Update
9th Nov 20237:00 amRNSNew Product Announcement
8th Nov 20237:00 amRNSChange of Nominated Adviser
7th Nov 20237:00 amRNSAppointment of New Auditors
2nd Nov 20237:00 amRNSHolding(s) in Company
24th Oct 20237:00 amRNSDirector/PDMR Dealing - Issue of Share Options
28th Sep 20237:00 amRNSNew Product Announcement
19th Sep 20237:00 amRNSInterim Results
6th Sep 20237:00 amRNSAcquisition of Phillips Aerospace
5th Sep 202312:04 pmRNSHolding(s) in Company
5th Sep 20237:00 amRNSNotice of Results
4th Sep 20231:20 pmRNSResult of General Meeting
25th Aug 20237:00 amRNSResult of Retail Offer
24th Aug 20233:07 pmRNSResult of AGM
16th Aug 20237:05 amRNSRetail Offer for up to £0.3 million
16th Aug 20237:00 amRNSProposed Acquisition and Notice of General Meeting
11th Aug 20233:15 pmRNSHolding(s) in Company
8th Aug 20237:00 amRNSNew Product Announcement
1st Aug 202310:58 amRNSNew Product Announcement
20th Jul 20237:00 amRNSNotification of Major Holdings
18th Jul 20237:00 amRNSPosting of Annual Report and Notice of AGM
17th Jul 20237:00 amRNSPost-Close Trading Update
30th Jun 20237:00 amRNSResults for the year ended 31 December 2022
19th Jun 20237:00 amRNSUpdate on Audited Annual Results
12th Jun 20237:00 amRNSSignificant Systems Win
9th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20237:00 amRNSNew Distributor Agreement
5th Jun 20237:00 amRNSNotice of Results
24th Mar 20237:00 amRNSNew Product Announcement
21st Mar 20237:00 amRNSReseller Agreement
4th Jan 20237:00 amRNSPost-Close Trading Update
14th Dec 20227:00 amRNSPartnership Agreement
28th Oct 20227:00 amRNSIssue of Share options and PDMR dealing
5th Oct 20227:00 amRNSConcurrent Technologies Enters the Systems Market
26th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
24th Aug 202210:29 amRNSHolding(s) in Company
24th Aug 202210:27 amRNSHolding(s) in Company
19th Aug 202212:06 pmRNSHolding(s) in Company
13th Jul 20227:00 amRNSSupply Agreement
29th Jun 202212:55 pmRNSResult of AGM
30th May 20227:00 amRNSPosting of Annual Report & Notice of AGM
23rd May 20222:46 pmRNSIssue of Share options and PDMR dealing
12th May 20227:00 amRNSResults for the year ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.